A subsidiary of Health Yuan (600380.SH) obtained a notice of approval for drug clinical trials

Zhitong Finance App News, Health Yuan (600380.SH) issued an announcement. Recently, Lizhu Group Lizhu Pharmaceutical Factory (abbreviation: Lizhu Pharmaceutical Factory), a holding subsidiary of the company's holding subsidiary, has received the approval and issuance of the “Drug Clinical Trial Approval Notice” (Notice No.: 2025LP03436, 2025LP03437) of NS-041 tablets for “treatment of depression”, and agreed to conduct clinical trials with NS-041 tablets for additional indications.

NS-041 tablets are a novel highly selective KCNQ2/3 agonist. It is aimed at treating neuropsychiatric diseases such as epilepsy and depression. It is currently the only KCNQ2/3 targeted drug approved in China to simultaneously conduct clinical studies on epilepsy and depression. On December 27, 2023, NS-041 tablets were approved to conduct clinical trials for the “epilepsy” indication. Currently, this indication is undergoing phase II clinical research. The newly approved clinical trial indication for NS-041 tablets is “treatment of depression.”